Treatment Delays With CAR-T Therapy: A High Price to Pay
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
CAR-T Therapy
Rationale for Mesothelin-Directed CAR-T Therapy in Metastatic, KRAS-Mutant Lung Adenocarcinoma
Preclinical studies performed in cell line and mouse models of lung adenocarcinoma showed that mesothelin-directed CAR-T was effective and not associated with toxicity.
Consensus Opinion Addresses Concerns About Clinical Application of CAR-T
A global task force makes recommendations for safe and appropriate use.
Measuring Low-Density Antigen Expression in Myeloma Cells Could Identify More Candidates for CAR-T Therapy
The antigen expression level on tumors that is necessary to engage and activate CAR-T cells is not currently known.
Tisagenlecleucel Appears Safe, Shows Activity in Secondary CNS Lymphoma
Tisagenlecleucel appeared to be safe and showed clinical activity in a small group of patients with secondary CNS lymphoma.
T-Cell Cryopreservation for Use in Future Cancer Treatment: Hot or Hype?
Can healthy immune cells from a patient be frozen and used in the future to make adoptive cell therapies in the event of a cancer diagnosis?
Waiting for CAR-T
Choosing the best bridging therapy for a patient, prior to administration of CAR-T, is dependent on the patient’s disease characteristics.
Facilitating CAR-T Cell Therapy in Solid Tumors Through “Vaccine Boosting”
Bispecific CAR-T cells were engineered to target both tumor antigen and vaccine-specific antigens to boost CAR-T function through an amphiphilic vaccine.
CAR-T Therapy Injected Directly Into Chest Cavity Shows Early Promise in Pleural Cancers
Early results from a phase 1 clinical trial of CAR T cells administered directly into the chest cavity for the treatment of pleural cancers has shown low toxicity and high efficacy.
Early MRD Status After CAR-T Administration Predicted PFS, OS
An analysis of patients in the ZUMA-1 trial found that day 28 minimal residual disease levels could identify patients at risk for early progression.
- Loading...
Loading...
Next post in ASCO 2019
Loading... 
Loading...